Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 948 clinical trials
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

of epcoritamab in combination with other standard of care (SOC) agents in subjects with B-cell Non-Hodgkin Lymphoma (B-NHL).

measurable disease
b-cell lymphoma
cytarabine
prednisone
lenalidomide
  • 5 views
  • 02 May, 2022
  • 61 locations
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

chronic lymphocytic leukemia
leukemia
hodgkin's disease
lymphoid leukemia
lymphoma
  • 13 views
  • 16 Jun, 2022
  • 8 locations
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

  • 0 views
  • 20 Jul, 2022
  • 18 locations
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab

cancer
b-cell lymphoma
prednisone
cyclophosphamide
large b-cell lymphoma
  • 0 views
  • 16 Sep, 2022
  • 13 locations
A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)

This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, …

aggressive non-hodgkin's lymphoma
follicular lymphoma
b-cell lymphoma
rituximab
  • 0 views
  • 18 Sep, 2022
  • 26 locations
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

leukemia
chronic lymphocytic leukemia
waldenstrom's macroglobulinemia
marginal zone lymphoma
follicular lymphoma
  • 0 views
  • 19 Sep, 2022
  • 21 locations
A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

This study is a phase I/II open-label study in patients with relapsed indolent NHL (Part A) or relapsed/refractory FL (Part B). Part A of the study assessed the safety and preliminary efficacy

measurable disease
hodgkin's disease
indolent non-hodgkin lymphoma
platelet count
alkylating agent
  • 406 views
  • 24 Jan, 2022
  • 94 locations
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. (DOBL)

The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20

chop regimen
cancer
hodgkin's disease
b-cell lymphoma
r-chop regimen
  • 83 views
  • 25 Feb, 2022
  • 1 location
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU)

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma

anthracyclines
hodgkin's disease
b-cell lymphoma
cell transplantation
aggressive non-hodgkin's lymphoma
  • 238 views
  • 31 Jan, 2022
  • 74 locations
A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This …

hodgkin's disease
b-cell lymphoma
measurable disease
cancer
obinutuzumab
  • 387 views
  • 14 Sep, 2022
  • 22 locations